SCHEMBL30104620

SCHEMBL30104620

CCCCCCCCCCCCCCCCCC(=O)O[C@H](C)C(=O)O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.69
MAPT P10636 5/20 0.59
MAPK1 P28482 5/20 0.59
ALDH1A1 P00352 1/20 0.56
DGKA P23743 1/20 0.52
PAM P19021 2/20 0.52
PRKCA P17252 1/20 0.51
PRKCE Q02156 1/20 0.51
PRKCQ Q04759 1/20 0.51
PRKCD Q05655 1/20 0.51
MEN1 O00255 3/20 0.51
GMNN O75496 3/20 0.51
KMT2A Q03164 3/20 0.51
NPSR1 Q6W5P4 3/20 0.51
CYP1A2 P05177 2/20 0.51
HSP90AA1 P07900 2/20 0.51
BLM P54132 2/20 0.51
NR1H4 Q96RI1 2/20 0.51
TP53 P04637 1/20 0.51
CYP2C9 P11712 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26302871 1.00 LMNA (0.69) LMNAMAPTMAPK1ALDH1A1DGKA
SCHEMBL18206743 1.00 LMNA (0.69) LMNAMAPTMAPK1ALDH1A1DGKA
SCHEMBL28615131 1.00 LMNA (0.69) LMNAMAPTMAPK1ALDH1A1DGKA
SCHEMBL8106034 1.00 LMNA (0.69) LMNAMAPTMAPK1ALDH1A1DGKA
SCHEMBL11354234 1.00 LMNA (0.69) LMNAMAPTMAPK1ALDH1A1DGKA
SCHEMBL1527349 1.00 LMNA (0.69) LMNAMAPTMAPK1ALDH1A1DGKA
Octane SCHEMBL3694961 1.00 LMNA (0.69) LMNAMAPTMAPK1ALDH1A1DGKA
SCHEMBL6630577 1.00 LMNA (0.69) LMNAMAPTMAPK1ALDH1A1DGKA
SCHEMBL8096798 1.00 LMNA (0.69) LMNAMAPTMAPK1ALDH1A1DGKA
SCHEMBL26197073 1.00 LMNA (0.69) LMNAMAPTMAPK1ALDH1A1DGKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240092745-A1 DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS Graybug Vision, Inc. (US) 2024-03-21 US disclosed
US-11548861-B2 Drugs and compositions for the treatment of ocular disorders Graybug Vision, Inc. (US) 2023-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11548861-B2 Drugs and compositions for the treatment of ocular disorders PDE6C, PDE6A, PDE6D LMNA 1432/4885MAPT 212/4885MAPK1 884/4885
US-20240092745-A1 DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS PDE6C, PDE6A, PDE6D LMNA 1432/4885MAPT 212/4885MAPK1 884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.